23-LUN-134-OC4(Preserve-003): Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

Grants and Contracts Details

StatusActive
Effective start/end date1/8/24 → 1/8/26

Funding

  • OncoC4 Incorporated: $46,923.00